Bild zu Biopharm

Erectile dysfunction

rhGDG-5 has also shown a high potential to treat Erectile Dysfunction after Radical Prostatectomy.

Prostatectomy is the Gold Standard to treat Prostata Carcinoma (186.000 prostatectomies in USA in 2010). 45% to 75% of patients remain with severe nerve damage, many of them life long after prostatectomy. Current therapy with PDE-5 inhibitors (Viagra) has limited success due to failure of nerve damage repair with pharmaco-therapy.

Pre-clinical Studies of BIOPHARM evidence that the application of rhGDF-5 enhances the recovery of erectile function in a rat model of cavernous nerve injury by 89% with easy injection, low dose (0.4 µg in rat model) and low cost (0.5 €/µg rhGDF-5).

The following figure shows an intracavernous application of growth differentiation factor-5 (GDF-5) after cavernous nerve injury:

(a) Healthy rodents (control 1)

(b) Damaged without rhGDF-5 treatment (control 2)

(c) Damaged & treated with 0.4 µg rhGDF-5.

Compared to existing therapies, rhGDF-5 seems also to be the best solution, according to literature:

We are now looking for an opportunity to license out this product for further clinical development and commercialization. Please contact us for additional information.